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Results and Discussion {#sec1}
======================

When cells enter M phase, a burst of morphological changes occurs, resulting in a profound reorganization of various cellular compartments in preparation for chromosome segregation and cell division. These changes are driven by Ser/Thr phosphorylation of over a thousand proteins, predominantly by cyclin-dependent kinase 1 (Cdk1) in complex with cyclin B (CycB) \[[@bib7], [@bib8]\]. Thus, Cdk1:CycB activation is the crucial event leading to mitosis, and the dynamics of this process have long been a focus of theoretical exploration. A key activation step of this kinase is the removal of Wee1/Myt1-dependent inhibitory phosphorylations of Cdk1 at Thr14/Tyr15 by Cdc25 phosphatases. Both inhibitory kinases and activating phosphatases are linked via positive feedback with Cdk1, creating bistability in Cdk1 activity with respect to total CycB ([Figure 1](#fig1){ref-type="fig"}A) \[[@bib3]\]. The bistable switch, well-known in engineering \[[@bib9], [@bib10]\], creates two distinct states, corresponding to interphase and M phase, without allowing the cell to come to rest in intermediate transitional states. There are distinct thresholds for mitotic entry and mitotic exit, so that once a cell accumulates enough CycB and commits to mitotic entry, it will only exit mitosis at a lower CycB level. This difference in thresholds provides robustness of the M phase state and prevents the cell from flipping back to the interphase state in the noisy cellular environment. Bistability of the mitotic switch system was confirmed in *Xenopus* extracts \[[@bib4], [@bib5]\] but has not been directly tested in intact mammalian cells. Moreover, the original Novak/Tyson mitotic switch model presumed a constitutive Cdk1-counteracting phosphatase, whose identity was unknown at the time. In recent years, however, it has become apparent that Cdk1-counteracting protein phosphatases (PP1 and PP2A) are also under stringent regulation \[[@bib11], [@bib12]\]. The best example for this is PP2A with its B55 regulatory subunit (PP2A:B55), which is tightly regulated by Greatwall (Gwl) kinase \[[@bib13]\] via its substrates ENSA and ARPP19 that become potent PP2A:B55 inhibitors upon phosphorylation \[[@bib14], [@bib15]\]. Gwl itself is activated by Cdk1-dependent phosphorylation \[[@bib16]\], which is reversed by PP1 \[[@bib17], [@bib18], [@bib19]\] and PP2A:B55 \[[@bib6], [@bib20]\], and the latter creates a mutual antagonism. Reconstitution of the Gwl-ENSA-PP2A:B55 pathway *in vitro* confirmed these interactions and revealed that PP2A:B55 has a bistable activity with respect to Cdk1 activity \[[@bib6]\] ([Figure 1](#fig1){ref-type="fig"}B). What remains to be determined is how these two bistable switches of Cdk1:CycB and PP2A:B55 are interlinked during interphase--M phase transitions in the context of the somatic mammalian cell cycle. Given that Cdk1 influences PP2A:B55 activity via Gwl and PP2A:B55 negatively regulates Cdk1 via Wee1 and Cdc25 \[[@bib21]\], one can imagine that the two feedback systems might reinforce each other, thereby increasing the robust separation of interphase and M phase states ([Figure 1](#fig1){ref-type="fig"}C). However, Gwl depletion and genetic deletion in mammalian cells results only in minor delays in the G2/M transition and does not interfere with establishing the mitotic state and initiating cell division \[[@bib22], [@bib23], [@bib24]\]. Thus, the precise contributions of the Cdk1 activation and PP2A:B55 inhibition feedback network to the G2/M switch system remain to be determined.Figure 1Bistable Switches of Mitotic Control(A--C) Schematic signal-response (SR) diagram for Cdk1 auto-activation (A), PP2A:B55 feedback regulation (B), and mitotic substrate phosphorylation by interlinked kinase--phosphatase switches (C).(D) Model of the hysteresis assay based on Cdk1 inhibition. The Cdk1 inhibitor shifts the SR curve to the right in a concentration-dependent manner: more inhibitor is required to induce mitotic exit (right curve) than to block mitotic entry (middle curve).(E) Summary: Cdk1 inhibitor blocks mitotic entry and promotes mitotic exit.

We set out to establish a quantitative assay for interphase--M phase bistability in human cells. A key feature of mitotic bistability is hysteresis---mitotic entry requires a larger cyclin B level than that required to block the reverse transition at mitotic exit ([Figure 1](#fig1){ref-type="fig"}C). We reasoned that hysteresis of mitotic transitions could also be quantitatively assessed by exposing cells to increased concentrations of a Cdk1 inhibitor that shifts the S-shaped substrate phosphorylation curve to the right ([Figure 1](#fig1){ref-type="fig"}D). If the mitotic switch is bistable and shows hysteresis, the threshold concentration of Cdk1 inhibitor required to block mitotic entry (θ~entry~) should be smaller than the one needed to induce mitotic exit (θ~exit~) at a given cyclin B level ([Figure 1](#fig1){ref-type="fig"}D).

To test this prediction, we used an analog-sensitive mutation in Cdk1 (cdk1as) that allows specific and reversible inhibition with the ATP analog 1NM-PP1 \[[@bib25], [@bib26]\] ([Figures 1](#fig1){ref-type="fig"}E, [S1](#mmc1){ref-type="supplementary-material"}A, and S1B). Thus, measuring the 1NM-PP1 concentrations required to prevent entry into mitosis and to trigger mitotic exit should allow us to determine θ~entry~ and θ~exit~. To simplify this assay, we performed G2/M synchronization of cdk1as cells (i.e., arresting them in G2 by 1NM-PP1 treatment and releasing them from G2 into mitosis) and used proteasome inhibition throughout the experiment to ensure constant cyclin B levels (see [Figure 2](#fig2){ref-type="fig"}A for experimental setup and [Figure 2](#fig2){ref-type="fig"}B and [Video S1](#mmc2){ref-type="supplementary-material"} for an example of a mitotic entry and exit experiment).Figure 2Hysteresis of Mammalian Mitotic Control(A) Experimental protocol to measure threshold 1NM-PP1 concentrations at constant CycB levels in cdk1as cells (see [Figure S1](#mmc1){ref-type="supplementary-material"} for characterization of cdk1as cells and [STAR Methods](#sec2){ref-type="sec"} for details of how they were generated).(B) Still images from time-lapse videos (see also [Video S1](#mmc2){ref-type="supplementary-material"}) of HeLa cdk1as cells released from 20-hr 1NM-PP1 arrest (entry, top two panels) or treated with 2 μM 1NM-PP1 90 min after mitotic arrest in MG132 (exit, bottom two panels). Time in minutes from release into MG132 (top panels) or from 1NM-PP1 add-back (bottom panels) is shown. Scale bars indicate 10 μm.(C) Galleries of nuclei from HeLa cdk1as cells, imaged 4 hr after entry and exit treatments (1NM-PP1 concentrations in μM as indicated above the panels). For each panel, one hundred nuclei were randomly chosen by Olympus SCANR software. Interphase nuclei appear rounded and enlarged; mitotic nuclei are rod-shaped and condensed. The red lines indicate the borders upon which 1NM-PP1 is becoming active for either entry or exit.(D) Quantifications of entry and exit experiments in HeLa cdk1as cells (see [Figure S2](#mmc1){ref-type="supplementary-material"} for similar results with U2OS cdk1as cells). The values are means of three biological repeats (N = 100 per repeat), and error bars indicate SD.(E) Temporal dynamics of mitotic entry at increasing 1NM-PP1 concentrations from live-cell imaging analysis.(F) Levels of mitotic cyclins in G2- and M-arrested cells analyzed by immuno-blotting with indicated antibodies. Each panel shows four steps of a serial 1:1 dilution of extracts.

Video S1. Synchronous Mitotic Entry and Exit in HeLa cdk1as Cells, Related to Figure 2BHeLa cdk1as cells were incubated for 20 hours with 2 μM 1NM-PP1 and 1 μM sirDNA. Inhibitor-containing medium was removed by washing the cells five times in drug-free medium. Finally, cells were taken up in medium containing 25 μM MG132 and 1 μM sirDNA and imaged in widefield/DIC and Far-red fluorescence channels (left panel, entry). The same cells shown in left panel after 3h 30 min of imaging were re-treated with 2 μM 1NM-PP1 to cause mitotic exit (right panel, Exit).

These highly synchronous mitotic entry and exit experiments allow a quantitative assessment of the Cdk1 inhibitor thresholds on these cell-cycle transitions. To obtain these measurements, we released HeLa cdk1as cells into increasing concentrations of 1NM-PP1 and tested for mitotic entry. For exit experiments, cells were released into 1NMPP-free medium and subsequently forced out of the mitotic state by increasing 1NM-PP1 concentrations. To assess the percentage of cells in mitosis and interphase following a dose-response curve with 1NM-PP1, we used an endpoint assay 4 hr after 1NM-PP1 addition and scored for interphase or mitosis by the morphology of Hoechst-stained DNA as shown in [Figure 2](#fig2){ref-type="fig"}C. Representative galleries of Hoechst-stained single cells show a clear threshold to block entry at 0.2 μM 1NM-PP1. In contrast, a similar induction of mitotic exit was only achieved at doses between 0.4 and 0.8 μM 1NM-PP1, suggesting a 2- to 4-fold change in entry and exit thresholds. Quantification of these data revealed a half-maximal inhibitory concentration (IC~50~) change from 143 nM to 573 nM between entry and exit experiments ([Figure 2](#fig2){ref-type="fig"}D). A similar result was also obtained in U2OS cdk1as cells ([Figure S2](#mmc1){ref-type="supplementary-material"}A). We also followed cells entering mitosis by live-cell imaging and quantified the percentage of mitotic cells over time using an automated detection algorithm (see [STAR Methods](#sec2){ref-type="sec"}). The rate of entry into mitosis declined with increasing inhibitor concentrations ([Figure 2](#fig2){ref-type="fig"}E), with the mitotic population reaching saturation 2 or 3 hr following 1NM-PP1 addition for each condition. We noted that cells appeared less sensitive to 1NM-PP1 when imaged on the fluorescence microscope, suggesting that 1NM-PP1 might be affected by light exposure. This made a direct comparison between endpoint and live-cell assays difficult, but we proceeded with both strategies to confirm thresholds and saturation. The interpretation of these experiments requires identical mitotic cyclin levels during mitotic entry and exit experiments, and this was verified by immuno-blotting ([Figure 2](#fig2){ref-type="fig"}F).

Based on the hysteresis assay shown in [Figure 2](#fig2){ref-type="fig"}, we aimed to establish a mathematical model to simulate this experiment. This model was designed to test the contribution of phosphatase and kinase regulation to bistability and to perform parameter fitting to satisfy all experimental conditions. To this end, we used non-linear ordinary differential equations describing the feedback regulation of Cdk1 and PP2A:B55 (see [Figure 3](#fig3){ref-type="fig"}A for the basic wiring diagram; for details on the equations and parameters, see [STAR Methods](#sec2){ref-type="sec"}). To obtain experimental parameters for this model and to determine the contribution of individual feedbacks to bistability, we measured the hysteresis effect in HeLa cdk1as cells following Wee1 inhibition and Gwl depletion ([Figure S3](#mmc1){ref-type="supplementary-material"}A) both individually and in combination ([Figure 3](#fig3){ref-type="fig"}B). Wee1 inhibition only had a mild effect on hysteresis, shifting the mitotic entry curve toward increased 1NM-PP1 doses (midpoint around 300 nM), and did not significantly affect the mitotic exit curve. Gwl depletion had a more pronounced effect, shifting both entry and exit curves toward lower 1NM-PP1 (midpoints around 67 nM and 92 nM, respectively; [Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). The effect of Gwl depletion on the entry threshold was partially reverted by Wee1 inhibition, and we observed a complete collapse of hysteresis in these conditions (IC~50~s for entry and exit at 147 nM and 150 nM, respectively; [Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}C). Time course experiments of mitotic entry under the various conditions confirmed that saturation was reached between three to 4 hr ([Figure S3](#mmc1){ref-type="supplementary-material"}D). These data suggest that both PP2A:B55 and Cdk1 autoregulation contribute to bistability, which is only lost if both feedback systems become compromised. If the regulation of Cdk1 did not contribute to the bistability of the system, we would not expect to observe hysteresis with Gwl depletion, and if the regulation of PP2A:B55 did not contribute to the overall bistability, we would not expect to observe hysteresis with Wee1 inhibition.Figure 3Contribution of Cdk1 and PP2A:B55 Feedbacks to Hysteresis(A) Wiring diagram of the mitotic switch that forms the basis of the modeling for this paper.(B) Percentage of cells entering into (red) and staying in (blue) mitosis at different Cdk1 inhibitor concentrations. Control (left column), Wee1-inhibited (second column), Gwl-depleted (third column; see [Figure S3](#mmc1){ref-type="supplementary-material"}A for confirmation of depletion and [Figure S3](#mmc1){ref-type="supplementary-material"}B for a higher resolution of 1NM-PP1 concentrations for this condition), and both Wee1-inhibited and Gwl-depleted (right column) cells are shown, with means of 3 or 4 biological repeats (N = 100 per repeat) and errors bars indicating SD (see [Figure S3](#mmc1){ref-type="supplementary-material"}C for comparison of IC~50~s for the different experimental conditions and [Figure S3](#mmc1){ref-type="supplementary-material"}D for time course data).(C) Signal-response curves for mitotic substrate phosphorylation in single cells as a function of inhibitor concentration. Steady-state substrate phosphorylation is high (red), low (blue), or intermediate (orange).(D) Simulated population response of mitotic cells assuming log-normal CycB distribution among individual cells (see [Figure S3](#mmc1){ref-type="supplementary-material"}F for our estimation of cyclin B concentration in the population, on which this model was based).

The kinetic constants of the model were determined by fitting the model to the experimental data, with initial estimates from the literature, where available \[[@bib27]\]. To determine whether a cell is in interphase or M phase, we included a generic Cdk1/PP2A:B55 substrate in the model and set a threshold phosphorylation level for the interphase-M phase boundary. Based on immunofluorescence assays (see [Figure 4](#fig4){ref-type="fig"}E), we attributed this threshold to be 30% maximal substrate phosphorylation. Plotting the predicted steady-state phosphorylation level of the generic Cdk1/PP2A:B55 substrate against 1NM-PP1 concentration ([Figure 3](#fig3){ref-type="fig"}C) suggests that the model captures the salient features of the data. There is a clear difference between the 1NM-PP1 doses needed to block mitotic entry and forcing mitotic exit in the control case. When addition of Wee1 inhibitor is simulated, the 1NM-PP1 threshold of mitotic entry is increased, and that of exit is unchanged. This latter feature of the model requires that PP2A:B55 inhibits amplification of Cdk1 activity, which together with Cdk1-dependent Greatwall activation makes the kinase--phosphatase feedback systems mutually inhibitory, as proposed on [Figure 1](#fig1){ref-type="fig"}C. The hysteresis in this case is due to bistable PP2A:B55 activity ([Figure S3](#mmc1){ref-type="supplementary-material"}E). With Gwl depletion, the model has reduced bistability and both thresholds are reduced. PP2A:B55 is modeled to be constitutively active with this perturbation and dephosphorylates the regulators of Cdk1 and the generic Cdk1/PP2A:B55 substrate. The hysteresis in this case is due to bistable Cdk1 activity ([Figure S3](#mmc1){ref-type="supplementary-material"}E). A combination of Wee1 inhibition and Gwl depletion eliminates bistability in the model. We also simulated variance among the population of cells, assuming a log-normal distribution of total cyclin B ([Figure S3](#mmc1){ref-type="supplementary-material"}F), with good agreement to the experimental data ([Figure 3](#fig3){ref-type="fig"}D).Figure 4Testing Predictions of the Model(A) Explanation of the synchronization protocol to obtain cells arrested in prophase (see [Figure S4](#mmc1){ref-type="supplementary-material"}A for a simulation of this experiment based on the model).(B) Images of cyclin B1-GFP-tagged HeLa cdk1as cells released from 1NM-PP1 arrest and retreated with 1 μM 1NM-PP1 25 min after release (see [Figure S4](#mmc1){ref-type="supplementary-material"}B for characterization of the GFP knockin cells). Time after re-addition of 1NM-PP1 is indicated in minutes; scale bars correspond to 20 μm. Left panels show cells moving back to G2 (chromosome decondenses and cyclin B is exported and cells flatten); middle panels show cells moving to mitotic arrest (chromosome condensation, nuclear envelope breakdown, and cell rounding); right panels show cells that remain in prophase (chromosomes partially condensed, cyclin B remains nuclear, and cells remain rounded up). See also [Video S2](#mmc3){ref-type="supplementary-material"}.(C) Measurements of cytoplasmic versus nuclear cyclin B1 ratio in single cells (top panels). Quantification of cell-cycle states in cells treated as described in (B) 4 hr after 1NM-PP1 addition (bottom). N \> 20 in three independent experiments, error bars indicate SD.(D) Representative images of cells fixed 4 hr after 1NM-PP1 re-addition and stained by immuno-fluorescence with indicated antibodies. Scale bar, 10 μM.(E) Quantification of Cdk1 substrate phosphorylation, Cdk1 Y15 phosphorylation, and nuclear surface of cells in the G2/M and prophase steady states (data are from three independent experiments; N \> 40 per experimental repeat; error bars indicate SD; p values were assessed using an independent two-sample t test; significant \[^∗∗∗^p \< 0.001; ^∗^p \< 0.05\] p values are indicated).(F) Images of HeLa cells progressing through mitosis after combined Gwl depletion and Wee1 inhibition. Time intervals are indicated in hr:min; scale bars indicate 10 μm; see also [Videos S3](#mmc4){ref-type="supplementary-material"} and [S4](#mmc5){ref-type="supplementary-material"}.(G) Quantification of mitotic phenotypes from live-cell imaging in HeLa cells.(H) Cell-cycle profiles of MDA MB 231 cells following inducible Gwl knockout (see [Figure S4](#mmc1){ref-type="supplementary-material"}C for confirmation of depletion) and Wee1 inhibition based on Edu (replicating population) and PI (DNA content) staining and FACS analysis.(I) Average values for Edu-positive and negative S phase populations of MDA MB 231 cells after Gwl depletion and or Wee1 inhibition. Values are from three independent experiments; N = 10,000 per experiment; error bars indicate SD (see [Figure S4](#mmc1){ref-type="supplementary-material"}D for quantification of all cell-cycle phases).(J) Proliferation assays following increasing time of Wee1 inhibition in MDA MB 231 cells following Ctr and Gwl gRNA/Cas9 expression. Cells were counted based on Hoechst staining and nuclear segmentation 6 days after MK1775 pulse treatment. Values are from three independent experiments; N \> 500 per experiment; error bars indicate SD. p values were assessed using an independent two-sample t test. Significant (^∗∗∗^p \< 0.001) or non-significant (p \> 0.05) p values are indicated.(K) Colony-formation assays in MDA MB 231 cells following Ctr and Gwl gRNA/Cas9 expression and 24-hr incubation with MK1775 at the indicated concentrations. 5,000 cells were plated into each 6-well plate and stained and imaged 2 weeks after MK1775 pulse treatment.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

A surprising prediction of our mathematical model for the G2/M switch is the existence of a third stable steady state in between interphase and mitosis. This steady state did not appear in previous models but emerged as a feature of our model after fitting to all experimental conditions. The state is not observable during normal mitotic progression; therefore, using the model, we devised an experiment to test its existence. Our model suggests that cells can be captured in this hypothetical intermediate stable state if Cdk1 activity is partially reduced during the G2-M transition ([Figure S4](#mmc1){ref-type="supplementary-material"}A). To test this prediction, we used endogenously tagged CyclinB1-mVenus ([Figure S4](#mmc1){ref-type="supplementary-material"}B) as a prophase marker (i.e., nuclear localization of cyclin B and intact nuclear envelope \[NE\]) and followed cells that were released from 1NM-PP1 and re-exposed to increasing 1NM-PP1 concentrations 25 min after release ([Figure 4](#fig4){ref-type="fig"}A). Prophase cells with nuclear cyclin B that lost sufficient amounts of Cdk1 activity are expected to re-export cyclin B to the cytoplasm, as previously reported \[[@bib28]\] ([Figure 4](#fig4){ref-type="fig"}B, left panels), and insufficient Cdk1 inhibition would allow the cells to continue to M phase marked by nuclear envelope breakdown (NEBD) ([Figure 4](#fig4){ref-type="fig"}B, middle panels). We expected from the model that a fraction of cells should remain in prophase in this experiment, and we could indeed observe cells that kept nuclear cyclin B and remained rounded up but did not undergo NEBD ([Figure 4](#fig4){ref-type="fig"}B, right panels; see also [Video S2](#mmc3){ref-type="supplementary-material"}).

Video S2. Examples of Cells after Re-addition of 1NM-PP1 following Release, Related to Figure 4BHeLa cdk1as cells with endogenously tagged CyclinB1-GFP were released from 1NM-PP1 arrest as in Video S1 and retreated with 1 μM 1NM-PP1 25 minutes after initial release. Left panels show sirDNA (Far-red), middle panels show Cyclin B1-GFP and right panel show widefield/DIC images. The top row shows and example of a cell re-entering G2, with Cyclin B moving out of the nucleus. The horizontal middle panels show an example of a cells that remain sin prophase. The bottom panels show a cell moving toward mitosis.

We quantified the nuclear-cytoplasmic ratio of cyclin B in cells with intact nuclei. This resulted in a clear separation in a "back to G2 (i.e. loss of nuclear cyclin B)" versus "prophase (i.e. cyclin B remains nuclear)" population ([Figure 4](#fig4){ref-type="fig"}C, top two panels). The prophase population was only observed when Cdk1 inhibitor was added back following release from the G2 arrest and increased with increasing inhibitor dose to about 10% at 1 μM 1NM-PP1 ([Figure 4](#fig4){ref-type="fig"}C, bottom panel). We further characterized this prophase steady state by immuno-fluorescence ([Figure 4](#fig4){ref-type="fig"}D), probing for cyclin B, lamin, Cdk1 substrate phosphorylation, and Cdk1 Y15 phosphorylation. In cell populations that were released from 1NM-PP1 and re-treated with 1 μM 1NM-PP1, we could readily identify a population of prophase cells 4 hr after release from the G2 arrest, and we did not observe similar prophase cells 4 hr after release without re-addition of 1NM-PP1. These cells were characterized by nuclear cyclin B, partially condensed DNA, yet intact nuclear envelope as judged by lamin B staining ([Figure 4](#fig4){ref-type="fig"}D). Compared with G2 and M phase cells, the prophase cells showed intermediate levels of Cdk1 activity and Y15 dephosphorylation, as predicted by the model, and displayed a decreased nuclear area, suggesting an intermediate state of chromosome compaction ([Figure 4](#fig4){ref-type="fig"}D; quantification in [Figure 4](#fig4){ref-type="fig"}E).

We next aimed to investigate whether loss of bistability has consequences for mitotic progression and cell proliferation that could ultimately be of therapeutic benefit. We first analyzed the effects of loss of combined Gwl and Wee1 inhibition on mitotic progression in asynchronously dividing HeLa cdk1as cells. A large fraction of cells lacking both Gwl and Wee1 activity readily entered mitosis but subsequently failed to stabilize the metaphase state, reverting to an interphase state without any visible attempt at chromosome segregation and cytokinesis ([Figure 4](#fig4){ref-type="fig"}F; quantification in [Figure 4](#fig4){ref-type="fig"}G; see [Video S3](#mmc4){ref-type="supplementary-material"}). This response was unique to the combined loss of the Gwl/Wee1 condition and not observed in the controls that all exited mitosis with chromosome segregation and cleavage furrow formation ([Figure 4](#fig4){ref-type="fig"}H; [Video S4](#mmc5){ref-type="supplementary-material"}). This exit was also in marked difference to spindle assembly checkpoint slippage, in which Gwl-depleted cells left the mitotic state after attempting chromosome segregation and cytokinesis ([Video S4](#mmc5){ref-type="supplementary-material"}). This result suggests that loss of bistability does, indeed, result in a failure to stabilize the metaphase state and also in a failure to initiate progression through mitosis toward cell division and G1. To investigate whether the synergistic effects of Gwl/Wee1 double inactivation could be used to inhibit cell proliferation in a therapeutic setting, we analyzed cell-cycle progression and proliferation in the triple-negative breast cancer cell line MDA MB 231, where Gwl is depleted via doxycycline-inducible Cas9/gRNA \[[@bib29]\] ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Edu labeling and fluorescence-activated cell sorting (FACS) analysis showed a significant reduction in the replicating S phase population 24 hr after treatment with 0.25 and 0.5 μM of the Wee1 inhibitor MK1775 when Gwl was co-depleted ([Figures 4](#fig4){ref-type="fig"}H, 4I, and [S4](#mmc1){ref-type="supplementary-material"}D). A 24-hr pulse treatment with the Wee1 inhibitor also significantly reduced cell proliferation as judged by cell counts 6 days after treatment ([Figure 4](#fig4){ref-type="fig"}J) and colony formation assays ([Figure 4](#fig4){ref-type="fig"}K). This synergy dissipated in longer term treatments with Wee1 inhibitors where the toxicity of Wee1 inhibition alone appeared to become dominant ([Figure 4](#fig4){ref-type="fig"}J).

Video S3. Mitosis in Ctr siRNA-Transfected and Gwl siRNA-Transfected HeLa Cells after Wee1 Inhibition, Related to Figures 4F and 4GLeft Panels: HeLa cells transfected with Ctr siRNA were imaged in the presence of sirDNA 48 hours later. Right Panels: HeLa cells transfected with Gwl siRNA and treated with 1 μM MK1775.

Video S4. Mitosis in Gwl siRNA-Transfected, MK1775-Treated, and Gwl siRNA/STLC-Treated Cells, Relating to Figures 4F and 4GAs in Video S3. Left Panes: Cells transfected with Gwl siRNA, Middle Panels: Cells treated with 1 μM MK1775. Right Panel: Cells transfected with Gwl siRNAand treated with 5 μM STLC before initiating the imaging sequence.

Our results demonstrate that the mitotic switch in somatic human cells is bistable, clarify how Cdk1 and PP2A regulation contribute to the establishment of this switch, and provide a comprehensive quantitative model for mitotic transitions. Our observations suggesting that two interlinked bistable switches work together to stably separate interphase and M phase could reflect a paradigm also acting in other cellular switch systems \[[@bib30]\]. The network architecture of this switch allows transitions to be made between states with maximum theoretical efficiency \[[@bib31]\]. Our model is of predictive value as demonstrated by the discovery and verification of a new steady state in prophase. Although this steady state appears to be an integral feature of the dynamical switch system, it has not to our knowledge been described previously, and its physiological relevance remains to be addressed. Indeed, RPE-1 cells have been reported to stall in late G2 phase with nuclear cyclin B following DNA damage for several hours before Cyclin degradation and exit into senescence \[[@bib32], [@bib33]\]. It is tempting to speculate that this arrest point may be related to the prophase steady state observed in our study. Our results also suggest that abrogating bistability leads to an unstable mitotic state and to loss of the irreversible progression toward cell division. Accordingly, double inhibition of both Gwl and Wee1 causes an additive effect on proliferation in breast cancer cells ([Figures 4](#fig4){ref-type="fig"}H--4K). This synthetic lethality due to loss of bistability could be exploited therapeutically once specific Gwl inhibitors become available.

STAR★Methods {#sec2}
============

Key Resources Table {#sec2.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Monoclonal anti mouse Cyclin B1, (GNS11)ThermofisherCat\# MA5-14327/ lot SG2418437A; RRID: [AB_10980440](nif-antibody:AB_10980440){#interref0010}Monoclonal anti mouse Cyclin A2, (E23.1)AbcamCat\# ab38; RRID: [AB_304084](nif-antibody:AB_304084){#interref0015}Monoclonal anti mouse Cyclin B2, (A-2)Santa CruzCat\# sc-28303; RRID: [AB_627340](nif-antibody:AB_627340){#interref0020}Polyclonal anti goat Lamin B (c-20)Santa CruzCat\# SC 6216/ lot J2314; RRID: [AB_648156](nif-antibody:AB_648156){#interref0025}Monoclonal anti rabbit Phospho-CDK substrate motif (k/h pSP)Cell SignalingCat\# 94775/ lot 2; RRID: [AB_2714143](nif-antibody:AB_2714143){#interref0030}Polyclonal anti rabbit pY15Cell SignalingCat\# 91115/ lot 8; RRID: [AB_331460](nif-antibody:AB_331460){#interref0035}Polyclonal anti mouse MASTLSigmaCat\# HPA054273-10ul/ lot R72184; RRID: [AB_2682433](nif-antibody:AB_2682433){#interref0040}Monoclonal anti mouse CDK1 (A17)AbcamCat\# Ab18/ lot GR249349-1; RRID: [AB_2074906](nif-antibody:AB_2074906){#interref0045}Monoclonal anti mouse c-Myc (9E10)AbcamCat\# Ab32/ GR310953-3c; RRID: [AB_303599](nif-antibody:AB_303599){#interref0050}Monoclonal anti mouse Histone H3 pS10 (6.6.2)MilliporeCat\# 05-499/ lot 2465188; RRID: [AB_309763](nif-antibody:AB_309763){#interref0055}Polyclonal anti rabbit TubulinAbcamCat\# ab126165/ lot GR106527-3; RRID: [AB_11129937](nif-antibody:AB_11129937){#interref0060}Monoclonal anti rabbit GAPDH (6C5)AbcamCat\# ab8245/ lot 1903516; RRID: [AB_2107448](nif-antibody:AB_2107448){#interref0065}Donkey anti rabbit Alexa Fluor 647InvitrogenCat\# A31573/ lot 1820538; RRID: [AB_2536183](nif-antibody:AB_2536183){#interref0070}Donkey anti mouse Alexa Fluor 488InvitrogenCat\# A21202/ lot 440197; RRID: [AB_141607](nif-antibody:AB_141607){#interref0075}Donkey anti goat Alexa Fluor 594InvitrogenCat\# A11058/ lot 20047670; RRID: [AB_2534105](nif-antibody:AB_2534105){#interref0080}Goat anti rabbit immunoglobulins HRPDakoCat\# P0448/ lot 20030309; RRID: [AB_2617138](nif-antibody:AB_2617138){#interref0085}Goat anti mouse immunoglobulins HRPDakoCat\# P0447/ lot GR3185172-3; RRID: [AB_2617137](nif-antibody:AB_2617137){#interref0090}**Chemicals**1NMPP1CalBiochemCat\# 529581STLC ((+)-S-Trityl-L-cysteineSigmaCat\# 164739MG132SigmaCat\# 474787DoxycyclineSigmaCat\# D1822MK-1775SelleckchemCat\# S1525Dharmafect 1 transfection reagentDharmaconCat\# T-2001-01Greatwall siRNAQuiagensiRNA ID MASTL 06Edu ClickiT Labeling KitThermo FisherCat\# C10337sirDNASpirochromeCat\# CHF280.00**Experimental Models: Cell Lines**HeLa cdk1asBill EarnshawHeLa_asU2OS cdk1asHelfrid HocheggerU2OS_asMDA MB 231 Greatwall/Cas9Marcos Malumbres\[[@bib23]\]**Recombinant DNA**XLcdk1F80GP2APuro in pcDNA 3.1Bill EarnshawCdl1as_PuroXLcdk1F80GP2AZeo in pcDNA 3.1Bill EarnshawCdk1as_ZeoCyclinB-GFPP2ANeo targeting constructHelfrid HocheggerCyclinB-\_GFPP2ANeocdk1gRNA in pSpCas9(BB)-2A-PuroHelfrid HocheggerCdk1 gRNA**Software and Algorithms**G2/M modelBela Novaksee [STAR Methods](#sec2){ref-type="sec"}Phase contrast segmentation CodeAnotida Madzvamuse<https://figshare.com/s/9bf30d093d14fef64ca0>

Contact for Reagent and Resource Sharing {#sec2.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Helfrid Hochegger (<hh65@sussex.ac.uk>).

Experimental Model and Subject Details {#sec2.3}
--------------------------------------

### General cell line culture conditions {#sec2.3.1}

U2OS, HeLa and MDA MB 231 cells were cultured in Dulbecco's modified Eagle Medium supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin in a 37°C, 5% CO2 incubator.

### HeLa cdk1as cells (Human cervical cancer cell line, female) {#sec2.3.2}

HeLa Cdk1as were established by stably expressing Cdk1-F80G-myc using a T2A linked puromycin selection cassette cloned into pcDNA3.1, in HeLa MKK1 cells (A gift from Patrick Meraldi \[[@bib34]\],). Endogenous Cdk1 was then removed by CRISPR nuclease targeting using pX459 Cas9T2Apuro \[[@bib35]\], target sequence (5′ATTTCCCGAATTGCAGTACTAGG 3′).

### HeLa cdk1as cells with GFP tagged endogenous Cyclin B {#sec2.3.3}

The Cyclin B1 gRNA was designed in the vicinity of the C-terminal of the coding sequence of Cyclin B1 using Benchling CRISPR tool (<https://benchling.com/>). The sequences 5′ ACTAGTTCAAGAT-TTAGCCA 3′ were introduced into the vector pSpCas9(BB)-2A-Puro (PX459, acquired from Feng Zhang via Addgene (plasmid \# 48139)) V2.0 following the protocol described in \[[@bib36]\]. To make the targeting template, Gibson assembly was used to assemble into NotI-digested pAAV-CMV vector (gift from Stephan Geley, University of Innsbruck, Austria) the fragments in the following order: the upstream targeting region (954bp), a linker (5′ CGCCTCAGCGGCATCAGCTGCAGGAGCTGGAGGTGCATCTGGCTCAGCGG-CAGG 3′), mEmerald, P2A-neomycin and the downstream targeting region (824bp). To get CRISPR-resistant constructs, the sequences ACTAGTTCAAGATTTAGCCAAGG were mutated to AtTAGTcCAgGAccTAGCtAAaG. Mutations (lowercase letters) are silent and preferential codon usage was taken into account. Cas9-gRNA expressing and targeting plasmid were co-transfected in HeLa cdk1as cells using Fugene (Promega) according to manufacturers recommended protocol and integrants were selected in 200 μg/ml G418. And confirmed by Immuno-blotting.

### U2OS cdk1as cells (Human bone osteosarcoma epithelial cell, female) {#sec2.3.4}

U2OS cells were obtained from the GDSC tisscue culture facility and previously verified by ACTT's cell line authentication service. XLcdk1as expression and knock out of endogenous Cdk1 was established as for HeLa cdk1as cells, except that 5′AATCCATGTACTGACCAGGAGGG 3′ was used as the gRNA target sequence.

### MDA MB 231 Cells expressing inducible Greatwall-Cas9-gRNA (Human triple negative breast cancer cell line, female) {#sec2.3.5}

These triple negative breast cancer cells express a lentiviral Tet inducible Cas9/gRNA targeting Greatwall \[[@bib29]\]. Induction of Cas9 by 1μg/ml Doxycyclin results in Greatwall knock outs and depletion of the protein within 3 days (see Immunoblot confirmation in [Figure S4](#mmc1){ref-type="supplementary-material"}).

Method Details {#sec2.4}
--------------

### Modeling of mitotic entry and exit {#sec2.4.1}

We used nonlinear ordinary differential equations (ODEs) to describe the kinetics of Cdk1:CycB and PP2A:B55 regulation. The ODEs describe the rate of change of the concentration of proteins in the regulatory pathways with respect to time. We used exclusively law of mass action kinetics, approximating enzyme catalyzed reactions by second-order kinetics, ignoring the explicit enzyme--substrate complex (except for pENSA bound to PP2A:B55). Rate constants and rate functions are abbreviated by '*k*' and '*V'*, respectively, with subscripts referring to the enzyme and the substrate of the reaction.

Based on the experimental data the model should have some fundamental qualitative features. There should be bistability in the control, Wee1 inhibition, and Gwl depletion cases, with reduced bistability in the latter two. Bistabilty should be diminished in the combined Wee1 inhibition and Gwl depletion case.

Based on the 20 hour G2 block and use of proteasome inhibitor, we can assume that the protein levels are unchanged following the G2 block. This is particularly important for CycB, as well as proteins that are normally degraded during mitotic progression.

A generic substrate is phosphorylated by Cdk1:CycB and dephosphorylated by PP2A:B55:$$\frac{d\left\lbrack {Subp} \right\rbrack}{dt} = k_{Cdk1,Sub} \cdot V_{Cdk1} \cdot \left( {\left\lbrack {Sub_{Tot}} \right\rbrack - \left\lbrack {Subp} \right\rbrack} \right) - k_{B55,Sub} \cdot \left\lbrack {PP2AB55} \right\rbrack \cdot \left\lbrack {Subp} \right\rbrack$$Cdk1:CycB is dephosphorylated (and activated) by Cdc25 and phosphorylated (and inactivated) by Wee1:$$\frac{d\left\lbrack {CycB:Cdk1} \right\rbrack}{dt} = V_{Cdc25} \cdot \left( {\left\lbrack {CycB_{Tot}} \right\rbrack - \left\lbrack {CycB:Cdk1} \right\rbrack} \right) - V_{Wee1} \cdot \left\lbrack {CycB:Cdk1} \right\rbrack$$PP1 is inactivated when phosphorylated by Cdk1. PP1 reactivates itself *in trans*:$$\frac{d\left\lbrack {PP1} \right\rbrack}{dt} = \left( {k_{aPP1} + k_{aPP1a} \cdot \left\lbrack {PP1} \right\rbrack} \right) \cdot \left( {\left\lbrack {PP1_{Tot}} \right\rbrack - \left\lbrack {PP1} \right\rbrack} \right) - \left( {k_{iPP1} + k_{Cdk1,PP1} \cdot V_{Cdk1}} \right) \cdot \left\lbrack {PP1} \right\rbrack$$ENSA is phosphorylated by active Gwl and dephosphorylated by B55 when in complex with the phosphatase:$$\frac{d\left\lbrack {pENSA_{Tot}} \right\rbrack}{dt} = V_{Gwl} \cdot \left( {\left\lbrack {ENSA_{Tot}} \right\rbrack - \left\lbrack {pENSA_{Tot}} \right\rbrack} \right) - k_{catB55} \cdot \left\lbrack {pENSA:B55} \right\rbrack$$Gwl is phosphorylated (and activated) by Cdk1:CycB and Cdk2:CycA. Gwl is dephosphorylated (and inactivated) by PP2A:B55, PP1, and a constitutive phosphatase:$$\frac{d\left\lbrack {Gwlp} \right\rbrack}{dt} = \left( {k_{Cdk1,Gwl} \cdot V_{Cdk1} + k_{Cdk2,Gwl} \cdot \left\lbrack {Cdk2_{Tot}} \right\rbrack} \right) \cdot \left( {\left\lbrack {Gwl_{Tot}} \right\rbrack - \left\lbrack {Gwlp} \right\rbrack} \right) - \left( {k_{B55,Gwl} \cdot \left\lbrack {PP2AB55} \right\rbrack + k_{PP1,Gwl} \cdot \left\lbrack {PP1} \right\rbrack + k_{PPX,Gwl}} \right) \cdot \left\lbrack {Gwlp} \right\rbrack$$PP2A:B55 associates with phosphorylated ENSA, titrating the phosphatase away from other substrates. PP2A:B55 dephosphorylates pENSA to which it is bound:$$\frac{d\left\lbrack {PP2AB55} \right\rbrack}{dt} = \left( {k_{dis} + k_{catB55}} \right) \cdot \left\lbrack {pENSA:B55} \right\rbrack - k_{ass} \cdot \left\lbrack {PP2AB55} \right\rbrack \cdot \left( \left\lbrack {pENSA_{Tot} - \left\lbrack {pENSA:B55} \right\rbrack} \right\rbrack \right)$$Wee1 is phosphorylated (and inactivated) by Cdk1:CycB and Cdk2:CycA. Wee1 is dephosphorylated (and activated) by PP2A:B55 and a constitutive phosphatase:$$\frac{d\left\lbrack {Wee1} \right\rbrack}{dt} = \left( {k_{PPX,Y15} + k_{BB5,Wee1} \cdot \left\lbrack {PP2AB55} \right\rbrack} \right) \cdot \left\lbrack {Wee1p} \right\rbrack - \left( {k_{Cdk1,Wee1} \cdot V_{Cdk1} + k_{Cdk2,Wee1} \cdot \left\lbrack {Cdk2_{Tot}} \right\rbrack} \right) \cdot \left\lbrack {Wee1} \right\rbrack$$We include a second inhibitory phosphorylation of Wee1 with the same rate constants for each phosphosite \[[@bib37]\]:$$\frac{d\left\lbrack {Wee1pp} \right\rbrack}{dt} = \left( {k_{Cdk1,Wee1} \cdot V_{Cdk1} + k_{Cdk2,Wee1} \cdot \left\lbrack {Cdk2_{Tot}} \right\rbrack} \right) \cdot \left\lbrack {Wee1p} \right\rbrack - \left( {k_{PPX,Y15} + k_{B55,Wee1} \cdot \left\lbrack {PP2AB55} \right\rbrack} \right) \cdot \left\lbrack {Wee1pp} \right\rbrack$$Cdc25 is phosphorylated (and activated) by Cdk1:CycB and Cdk2:CycA. Cdc25 is dephosphorylated (and inactivated) by PP2A:B55 and a constitutive phosphatase:$$\frac{d\left\lbrack {Cdc25} \right\rbrack}{dt} = \left( {k_{PPX,Y15} + k_{B55,Cdc25} \cdot \left\lbrack {PP2AB55} \right\rbrack} \right) \cdot \left\lbrack {Cdc25p} \right\rbrack - \left( {k_{Cdk1,Cdc25} \cdot V_{Cdk1} + k_{Cdk2,Cdc25} \cdot \left\lbrack {CycA_{Tot}} \right\rbrack} \right) \cdot \left\lbrack {Cdc25} \right\rbrack$$We include a second activating phosphorylation of Cdc25 \[[@bib38]\] with the same rate constants for each phosphosite:$$\frac{d\left\lbrack {Cdc25pp} \right\rbrack}{dt} = \left( {k_{Cdk1,Cdc25} \cdot V_{Cdk1} + k_{Cdk2,Cdc25} \cdot \left\lbrack {CycA_{Tot}} \right\rbrack} \right) \cdot \left\lbrack {Cdc25p} \right\rbrack - \left( {k_{PPX,Y15} + k_{B55,Cdc25} \cdot \left\lbrack {PP2AB55} \right\rbrack} \right) \cdot \left\lbrack {Cdc25pp} \right\rbrack\ $$Cdk1 is inhibited by 1NM-PP1 (*Inh*~*Cdk1*~), which in steady state provides the following rate function:$$V_{Cdk1} = \frac{\left\lbrack {CycB:Cdk1} \right\rbrack}{1 + \frac{Inh_{Cdk1}}{K_{d}}}$$

Conservation of total PP2A:B55: $\left\lbrack {pENSA:B55} \right\rbrack = \left\lbrack {B55_{Tot}} \right\rbrack - \left\lbrack {PP2AB55} \right\rbrack$

Conservation of Wee1: $\left\lbrack {Wee1p} \right\rbrack = \left\lbrack {Wee1_{Tot}} \right\rbrack - \left\lbrack {Wee1} \right\rbrack - \left\lbrack {Wee1pp} \right\rbrack$

Conservation of Cdc25: $\left\lbrack {Cdc25p} \right\rbrack = \left\lbrack {Cdc25_{Tot}} \right\rbrack - \left\lbrack {Cdc25} \right\rbrack - \left\lbrack {Cdc25pp} \right\rbrack$

Wee1 and Cdc25 activities (rate functions) are the sum of their less- and more-active forms:$$V_{Wee1} = k_{Wee1S} \cdot \left( {\left\lbrack {Wee1_{Tot}} \right\rbrack - \left\lbrack {Wee1} \right\rbrack} \right) + k_{Wee1F} \cdot \left\lbrack {Wee1} \right\rbrack$$$$V_{Cdc25} = k_{Cdc25S} \cdot \left( {\left\lbrack {Cdc25_{Tot}} \right\rbrack - \left\lbrack {Cdc25pp} \right\rbrack} \right) + k_{Cdc25F} \cdot \left\lbrack {Cdc25pp} \right\rbrack$$Gwl rate function depends on the phosphorylated form: $V_{Gwl} = k_{Gwl,ENSA} \cdot \left\lbrack {Gwlp} \right\rbrack$

This system of differential and algebraic equations was solved with numerical integration, giving the protein concentrations in time. The model output can be interpreted with bifurcation diagrams, which depict the steady state response of a variable with respect to a changing parameter value. This allows for comparison with the end-point experiments in [Figure 3](#fig3){ref-type="fig"}B. For Wee1 inhibition, set the parameters $k_{Wee1S}$ and $k_{Wee1F}$ to 0. For Gwl siRNA, set the $\left\lbrack {Gwl_{Tot}} \right\rbrack$ parameter to 0. For [Figure S4](#mmc1){ref-type="supplementary-material"}A set $Inh_{Cdk\ 1}$ = 0.5 μM.

The experimental results are presented as 'mitotic cells', whereas the model has 'substrate phosphorylation'. To directly compare the two, we chose a 30% maximal substrate phosphorylation threshold for the mitotic state, which was based on our immuno-fluorescence quantifications. The bifurcation diagrams in [Figure 3](#fig3){ref-type="fig"}C can be compared with the experimental results in this way.

### Mathematical modeling of the variation within a population of cells {#sec2.4.2}

The nonlinear ordinary differential equations described above can describe the behavior of a single cell. To capture the variation observed between cells in the experiments heterogeneity has to be introduced into the model. We decided to simulate a log-normal distribution of total CycB level for the population of cells ([Figure S3](#mmc1){ref-type="supplementary-material"}F) based on \[[@bib39]\] with median 8.18 AU and standard deviation 4.31 AU. Since the total CycB level is assumed to remain constant after release from the G2 block, this involved changing just one parameter for each simulation. Simulating the experimental protocol *in silico* gave the results in [Figure 3](#fig3){ref-type="fig"}D, after parameter fitting.

### Estimation of the kinetic parameters of the model {#sec2.4.3}

Since the intracellular concentrations of proteins are largely unknown (with few exceptions), we have chosen the total concentrations of the following proteins (CycA:Cdk2, PP1, ENSA, Gwl, Wee1, Cdc25 and Sub) as one arbitrary unit, except B55~Tot~ = 0.25 and CycB~Tot~ = 8.18 (see below). Our zero- and second-order rate constants can be immediately converted into nM min^-1^ and nM^-1^ min^-1^ dimensions in view of protein concentrations in nM. We built a customised objective function within the parameter fitting routine MEIGO \[[@bib40]\] to parameterise the model. An initial parameterisation was performed using the 50% levels for each of the four experimental conditions. This determined a median cyclin B level. Next, the log-normal cyclin B distribution was used to fit all of the experimental data, and this time the variance of the cyclin B distribution was fitted. We used the values in \[[@bib27]\] as initial values for the binding and activity of PP2A:B55 toward pENSA. After fitting, the catalytic and association (after scaling) values were within 3--5-fold of the literature values. All the parameters and initial conditions are in the tables below.

Parameter values used in the model.NameDescriptionValue$Inh_{Cdk1}$Level of 1NM-PP1 added0--2 μM$k_{aPP1}$Constitutive dephosphorylation and thereby activation of PP10.01 min^-1^$k_{aPP1a}$Dephosphorylation of PP1 by dephosphorylated PP1 *in trans*0.70 min^-1^$k_{iPP1}$Constitutive phosphorylation and hence inactivation of PP10.002 min^-1^$k_{Cdk1,PP1}$Phosphorylation of PP1 by Cdk1:CycB0.75 min^-1^$k_{PP1,Gwl}$Dephosphorylation of Gwl by PP118.47 min^-1^$k_{ass}$Association of phosphorylated ENSA with PP2A:B55617 min^-1^$k_{dis}$Dissociation of the pENSA:PP2A:B55 complex0.009 min^-1^$k_{catB55}$Dephosphorylation of pENSA when in complex with PP2A:B551 min^-1^$k_{Gwl,ENSA}$Phosphorylation of ENSA by Gwl21 min^-1^$k_{PPX,Gwl}$Basal dephosphorylation of Gwl0.16 min^-1^$k_{Cdk1,Sub}$Phosphorylation of the substrate by Cdk1:CycB0.008 min^-1^$k_{Cdk1,Gwl}$Phosphorylation of Gwl by Cdk1:CycB0.24 min^-1^$k_{B55,Gwl}$Dephosphorylation of Gwl by PP2A:B55496 min^-1^$k_{B55,Sub}$Dephosphorylation of the substrate by PP2A:B550.06 min^-1^$k_{Cdk2,Gwl}$Phosphorylation of Gwl by Cdk20.19 min^-1^$k_{Cdc25S}$Dephosphorylation of Y15 of Cdk1 by unphosphorylated Cdc250.005 min^-1^$k_{Cdc25F}$Dephosphorylation of Y15 of Cdk1 by phosphorylated Cdc250.94 min^-1^$k_{Wee1S}$Phosphorylation of Y15 of Cdk1 by phosphorylated Wee10.005 min^-1^$k_{Wee1F}$Phosphorylation of Y15 of Cdk1 by unphosphorylated Wee147 min^-1^$k_{Cdk1,Wee1}$Phosphorylation of Wee1 by Cdk1:CycB1.31 min^-1^$k_{Cdk1,Cdc25}$Phosphorylation of Cdc25 by Cdk1:CycB1.31 min^-1^$k_{PPX,Y15}$Dephosphorylation of Wee1 and Cdc25 by a constitutive phosphatase0.005 min^-1^$k_{Cdk2,Wee1}$Phosphorylation of Wee1 by Cdk20.11 min^-1^$k_{Cdk2,Cdc25}$Phosphorylation of Cdc25 by Cdk20.11 min^-1^$k_{B55,Wee1}$Dephosphorylation of Wee1 by PP2A:B550.55 min^-1^$k_{B55,Cdc25}$Dephosphorylation of Cdc25 by PP2A:B550.55 min^-1^$K_{d}$Dissociation constant for 1NM-PP1 with Cdk10.025 min^-1^

Initial conditions correspond to interphase arrest.Dynamic variableInitial value$Subp$0$CycB:Cdk1$0$PP1$1$pENSA_{Tot}$0$Gwlp$0$PP2AB55$0.25$Wee1$1$Wee1pp$0$Cdc25$1$Cdc25pp$0

XPPAUT code for the bifurcation diagrams of [Figure 3](#fig3){ref-type="fig"}C, [Figure S3](#mmc1){ref-type="supplementary-material"}E, and [Figure S4](#mmc1){ref-type="supplementary-material"}A.Subp' = kcBc1Sub^∗^CycBCdk1/((1 + (InhCDK/Kd)))^∗^(SubT-Subp) - kB55Sub^∗^PP2AB55^∗^SubpCycBCdk1' = V25^∗^(CycBCdk1T - CycBCdk1) - Vwee^∗^CycBCdk1PP1' = (kapp1 + kapp1a^∗^PP1)^∗^(PP1T - PP1) - (kipp1 + kipp1C^∗^CycBCdk1/((1 + (InhCDK/Kd))))^∗^PP1pENSAt' = VGwl^∗^(ENSAtot - pENSAt) - kcatB55^∗^ComplexGwlp' = (kcBc1G^∗^CycBCdk1/((1 + (InhCDK/Kd))) + kcAc2G^∗^CycACdk2T)^∗^(Gwtot - Gwlp) - (kB55G^∗^PP2AB55 + kppxGwl + kPP1Gw^∗^PP1)^∗^GwlpPP2AB55' = kdis^∗^Complex + kcatB55^∗^Complex - kass^∗^PP2AB55^∗^(pENSAt - Complex)Complex = B55tot - PP2AB55Wee1' = (kppxY15 + kB55W1^∗^PP2AB55)^∗^Wee1p - (kcBc1W1^∗^CycBCdk1/((1 + (InhCDK/Kd))) ∖+ kcAc2W1^∗^CycACdk2T)^∗^Wee1Wee1pp' = (kcBc1W1^∗^CycBCdk1/((1 + (InhCDK/Kd))) + kcAc2W1^∗^CycACdk2T)^∗^Wee1p - ∖(kppxY15 + kB55W1^∗^PP2AB55)^∗^Wee1ppWee1p = 1 - Wee1 - Wee1ppCdc25' = (kppxY15 + kB5525^∗^PP2AB55)^∗^Cdc25p - (kcBc125^∗^CycBCdk1/((1 + (InhCDK/Kd))) + kcAc225^∗^CycACdk2T)^∗^Cdc25Cdc25pp' = (kcBc125^∗^CycBCdk1/((1 + (InhCDK/Kd))) + kcAc225^∗^CycACdk2T)^∗^(Cdc25p) - ∖(kppxY15 + kB5525^∗^PP2AB55)^∗^Cdc25ppCdc25p = 1 - Cdc25 - Cdc25ppVwee = (kweeS^∗^(1-Wee1) + kweeF^∗^Wee1)V25 = k25S^∗^(1-Cdc25pp) + k25F^∗^Cdc25ppVGwl = kGwENSA^∗^Gwlpinit Subp = 0, CycBCdk1 = 0, PP1 = 1, pENSAt = 0, Gwlp = 0, PP2AB55 = 0.25, Wee1 = 1, Wee1pp = 0, Cdc25 = 1, Cdc25pp = 0p InhCDK = 1, CycBCdk1T = 8.1808, CycACdk2T = 1.0000, PP1T = 1.0000, kapp1 = 0.0115p kapp1a = 0.7054, kipp1 = 0.0018, kipp1C = 0.7549, kPP1Gw = 18.4724p ENSAtot = 1.0000, B55tot = 0.2500, SubT = 1.0000, kass = 617.2807p kdis = 0.0088, kcatB55 = 1.0338, kGwENSA = 20.8811, kppxGwl = 0.1560, kcBc1Sub = 0.0080p kcBc1G = 0.2393, Gwtot = 1.0000, kB55G = 496.5636, kB55Sub = 0.0593p kcAc2G = 0.1916, k25S = 0.0050, k25F = 0.9411, kweeS = 0.0050, kweeF = 47.2937p kcBc1W1 = 1.3132, kcBc125 = 1.3132, kppxY15 = 0.0050, kcAc2W1 = 0.1096p kcAc225 = 0.1096, kB55W1 = 0.5511, kB5525 = 0.5511, Kd = 0.025@ total = 1000,dt = 0.1,meth = STIFF,xlo = 0,xhi = 100,ylo = 0,yhi = 1@ NTST = 15,NMAX = 1000000,NPR = 10000,DS = −0.001@ DSMAX = 0.005,DSMIN = 0.001,PARMIN = 0,PARMAX = 10@ AUTOXMIN = 0,AUTOXMAX = 0.8,AUTOYMIN = 0,AUTOYMAX = 1done

### Preparation of total cell extracts, immunoblotting {#sec2.4.4}

For cell lysate preparation 5 × 10E5 cells were washed once in PBS and lysed in 50 μL ECB buffer (50 mM Tris pH 7.5, 120 mM NaCl, 0.5% NP40, 1 mM EDTA, 0.05% β-mercaptoethanol and protease (1 tablet per 50 ml) and phosphatase (1 tablet per 10 ml) inhibitors, and incubated on ice for 20 min. Cells were sonicated. Protein concentrations were determined by Bradford method and lysates were equalized for protein concentration using ECB buffer. Samples were then resuspended in 1 × SDS--PAGE sample buffer (12.5 mM Tris--HCl pH 6.8, 1.4% (w/v) SDS, 4% sucrose (w/v), 0.002% (w/v) bromophenyl blue, 0.4 mM β-mercaptoethanol). Samples were then analyzed by western blotting.

### siRNA transfections {#sec2.4.5}

Cells were reverse transfected with 20 nM siRNA at a density of 0.4 × 105 cells/ml using Dharmafect 1 transfection reagent (Dharmacon) following the manufacturers' protocol. Eight hours following transfection the medium was changed and cells were synchronized with 1NM-PP1 24 hours later. Control and Greatwall siRNA (MASTL 06, 5′ACGCCTTATTCTAGCAAATTA3′) were purchased from QIAGEN.

### FACS analysis {#sec2.4.6}

Cells were incubated with 10 μM of EdU for 1h before being harvested and fixed in 70% ethanol. Next, EdU was labeled with the fluorophore Alexa 647 using Click-iT EdU Imaging Kit (Invitrogen) and DNA were stained with 5 μg/mL of propidium iodide (Fluka) and 150 μg/mL of RNaseA (Sigma-Aldrich). Facs profiles were obtained from data acquired on Accuri C6 Flow cytometer (BD Biosci-ences).

### Immunofluorescence and live cell imaging {#sec2.4.7}

HeLa cdk1as cells were grown on coverslips and fixed for 10 min in 3.7% formalde-hyde, rinsed 3 times in PBS. Coverslips were then rinsed in PBS and cells permeabilized in PBS-0.1% NP40. Cells were blocked in 2% BSA for 10 min and probed with primary antibodies (as indicated in figure legends) for 40 min. Slides/coverslips were rinsed 4 × in PBS and probed with Alexa secondary antibodies listed for 20 min. Slides/coverslips were then rinsed 4 × in PBS and coverslips were mounted using ProLong® Gold mounting solution containing DAPI (Invitrogen). For image acquisition, we used a Olymnpus IX73 microscope. Imaging was performed using a UPLanS Apo, N.A. 1.43, × 60 oil immersion objective (Olympus), standard filter sets (excitation 360/40; 490/20; 555/28; emission 457/50; 528/38; 617/40) and a Prime sCMOS camera (Photometrics). Z-series of 0.7 μm stacks were acquired using Micromanager software (Version 6.0.8) and images exported as tiff files. Images were analyzed in ImageJ. Regions were manually marked on the image for analysis and analyzed using the ImageJ ROI manager tool. Live cell imaging was performed on the Olympys IX73 microscope equipped with an environmental chamber (Digital Pixel), using either a 0.6NA 40x PlanFL long distance objective suitable for differential interference contracts imaging, or a 20x 0.45NA PlanFL long distance objective designed for phase contrast image acquisition in the wide field channel. Images were acquired using Micromanager software (Version 6.0.8) and recorded by a Prime sCMOS camera at 37C Temperature and 5% CO2. Environmental conditions were maintained by an environmental chamber from Digital Pixel.

### Bistability Assay {#sec2.4.8}

HeLa cdk1as cells were plated at a density of 7500 cells into 96 well half area high content imaging glass bottom microplates (Corning, 4580). U2OS cdk1as cells were plated in 96 well plates (Perkin Elmer Cell carrier- 96 Ultra) that were coated with 40 μL of a 1/10 dilution in PBS of Collagen1 (Pan Biotech) and left to dry in a tissue culture hood. Before plating cells, collagen was activated by washing with PBS two times. Cells were plated at the same density as HeLa cdk1as cells. 24 hours later medium was changed to medium containing 2 μM 1NM-PP1. Following 20 hour 1NM-PP1 incubation the mitotic exit samples were washed 5 times with medium, following the last wash 50 μl medium containing 25 μM MG231 was added. 90 minutes later the mitotic exit samples were washed in the same way and released in 25 μM MG231 medium. Finally, 50 μl medium with 25 μM MG231 and 2x concentrations of the indicated inhibitors was added. Cells were fixed after a further four hour incubation by adding 10 μl 3.4% Formaldehyde for 10 minutes. Subsequently the fixation medium was removed and resuspended in PBS containing 2 μM Hoechst 33342 (Thermofisher). Imaging was performed on a Olympus IX81 SCANR microscope using a 0.4 NA PlanFL 20x long distance objective, with a camera ORCA-R2(Hamamatsu CCD). Nuclei were segmented using a bespoke SCANR algorithm based on pixel intensity and 100 random nuclei per well were displayed using the SCANR gallery tools and counted manually.

### Automated measurement of mitotic index in live cell experiments {#sec2.4.9}

We developed a bespoke MATLAB script to count the number of mitotic cells in a time lapse experiment. This is based on estimating the total number of cells in the field of view based on segmentation of the sirDNA stained nuclei using a standard Otsu algorithm \[[@bib41]\]. Mitotic cells were detected by the change in intensity in the phase contract channel during cell rounding. To identify the resulting bright halo circles in the segmentation, we employed an algorithm based on a circular Hough Transform \[[@bib42]\] and filtered the identified objects by circularity and size.

Quantification and Statistical Analysis {#sec2.5}
---------------------------------------

All experiments included at least three independent biological repeats. Sample size per repeat varied between experiments and are indicated in the Figure Legends as well as Mean, Standard Deviation or Median values. Sample size was based on standard practise in cell biological assays and not specifically pre-estimated. P values were calculated using a 1 tail unequal variance t test. For all experiments, samples were not randomized and the investigators were not blinded to the group allocation during experiments and outcome assessment. No exclusion criteria were used and all collected data were used for statistical analysis.
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